All posts by admin

Drug Channels News Roundup, February 2021: Accumulator Problems, Humana + ESI, White Bagging Battles, Buy-and-Bill Economics, and Pharmacy Hero Dave Marley

Let’s melt away this foul February with our monthly selection of scorching news from around the drug channel. In this issue:

  • Payers confess: Patients lose from copay accumulators
  • Humana joins the Express Scripts GPO
  • Hospitals vs. PBMs over specialty pharmacy white bagging
  • Let’s all follow the Buy-and-Bill Dollar!

Plus, entrepreneurial pharmacy owner Dave Marley demonstrates the power of innovation.

P.S. Join the more than 11,000 followers of my daily links to neat stuff at @DrugChannels on Twitter. You can also join my more than 15,000 followers on LinkedIn.



Copay Accumulators: Shifting Cost Of Care From Plan Sponsors To Patients?, MME

Wow. In a startling survey, pharmacy and medical directors from 24 insurers (representing 229 million covered lives) have actually admitted that copay accumulators are bad for patients.

Survey highlights:

  • About 60% of payers strongly agree that accumulators have the potential to shift costs from plan sponsors to patients.
  • A majority (54%) of payers agree accumulators could adversely impact patient medication adherence.
  • Approximately one out of four payers strongly agrees that accumulators could have the potential to discourage appropriate utilization of specialty therapies.

Despite these responses, more than half of payers believe that cost containment strategies should not limit patients’ ability to receive access to appropriate care. Huh?

These discouraging results reinforce my cynicism about payers’ true motivations for this patient-unfriendly benefit design. Nonetheless, adoption of copay accumulators continues to roar ahead. (See Copay Accumulator and Maximizer Update: Adoption Accelerating As Pushback Grows.)

Yuck.

Humana to Join Cigna Drug-Buying Group for Some Members, Bloomberg

This Bloomberg scoop highlights the ever-growing consolidation of PBMs’ negotiating power.

In April 2021, Humana will begin sourcing formulary rebates for its commercial health plans via Ascent Health Services, Express Scripts’ secretive, Switzerland-based group purchasing organization (GPO). Humana’s fully insured commercial and ASO medical membership accounted for just under 12% of its non-military medical membership as of December 31, 2020.

Ascent already handles rebate negotiations for Express Scripts’ PBM business, Prime Therapeutics, and Kroger Prescription Plans. For background, see Express Scripts + Prime Therapeutics: Our Four Takeaways From This Market Changing Deal.

Re: UnitedHealthcare Coverage Policies, American Hospital Association

The battle for specialty drug margin rages on.

Payer-owned specialty pharmacies—via white, brown, and clear bagging—are trying to displace buy-and-bill distribution channels for provider-administered specialty drugs. Such moves would boost profits for PBM-owned specialty pharmacies, which focus primarily on patient-administered products. For background, see Specialty Pharmacy Keeps Disrupting Buy-and-Bill—and COVID-19 Will Accelerate It.

Hospitals naturally want to retain the often enormous mark-ups on these products. Hence, the American Hospital Association wrote to CMS to “express deep concerns” about UnitedHealthcare’s white bagging policies for provider-administered specialty drugs.

This clash of the vertically integrated titans has been brewing for years. More to come.

Follow the Dollar Part II: Understanding the Cost of Brand Medicines Administered to Commercially Insured Patients in Hospital Outpatient Departments, PhRMA

This valuable new PhRMA white paper explains the follow-the-dollar math for buy-and-bill products at hospitals. See page 15 (reproduced below). It illustrates how a 340B hospital can earn three times what the manufacturer earns from a provider-administered product. (The paper also shows a non-340B example.)

[Click to Enlarge]

This paper will help you understand why hospitals fight any reforms to the 340B Drug Pricing Program—and lobby against white bagging. The examples are highly consistent with Ronny Gal’s outstanding analysis of hospitals’ massive markups. Check out the eye-popping figures shown in the Drug Channels January 2021 news roundup.

Medicure Enters the US Online Pharmacy World with Acquisition of Marley Drug, PR Newswire

Sometimes, the little guy wins big.

Dave Marley has just sold Marley Drug, the independent pharmacy he founded in 2003, to Medicure Pharma. Marley Drug generated $1.7 million in profits on revenues of $7.0 million.

I’ve known Dave for almost 10 years. He is a true entrepreneur who has always been willing to push back against the industry’s received wisdom. Dave spotted the business opportunity for a low cost, mail-order generic drug program targeted at employers and health plans. Crucially, his business didn’t depend on PBMs.

Check out this profile of the business, along with lovely photos of Dave and Elizabeth Marley: Marley Drug changes ownership as experiment in how consumers purchase prescription drugs .

Dave is also a great human. The Marleys have already started sharing their success by funding a charitable trust for Second Harvest Food Bank and the Bethesda Center for the Homeless

Congratulations, Dave!

       

Source: Post feed

The Promise and Limits of Digital Pharmacies

Does pharmacy need to be disrupted?

Venture capitalists clearly think so, judging by the billions they have put behind technology-enabled digital pharmacies. Below, you’ll find our list of 14 leading contenders along with funding levels. These companies have not gained significant pharmacy industry market share, but their revenue growth rates are impressive.

Alas, many of these digital pharmacies seem to have misdiagnosed their relative advantage versus today's pharmacies. 

That’s why I believe that digital pharmacies’ biggest impact will come from forcing the industry incumbents to improve their businesses and approach to patients. Pharmacies and PBMs should absorb the technologies and consumer-oriented mindsets of the start-ups.
Digital pharmacies more intriguing disruption comes from combining prescribing and dispensing. But this novel idea seems to have limited applicability to the broader prescription market.   

Read on and let me know what you think.

Read more »

        

Source: Post feed

Available for Preorder: The 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

On March 16, 2021, Drug Channels Institute will release The 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. This report—our twelfth edition—remains the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system.

We are providing you with the opportunity to preorder this thoroughly updated and revised 2021 edition at special discounted prices. This means that you can be among the first to access our new report. Those who preorder will receive a download link before March 16.

CLICK HERE to download a free pre-publication overview

(including key industry trends, the Table of Contents, and a List of Exhibits)
.

You can pay online with all major credit cards (Visa, MasterCard, American Express, and Discover) or via PayPal. Click here to email us if you would like to pay by corporate purchase order or check.

Special preorder and launch pricing discounts will be valid through March 28, 2021.

Read more »

        

Source: Post feed

Pharmacy Economics Rebound (A Little) Amid Glimmers of Good News

Time to update Drug Channels' exclusive look at independent pharmacy owners’ business economics.

Our analysis reveals that despite what you may have heard, many independent pharmacies have figured out how to survive a highly challenging environment.

Retail pharmacy profits have rebounded—or at least not fallen any further. What’s more, better expense control has allowed the average pharmacy owner’s salary to increase for the first time in years. 

Believe it or not, the pharmacy profit outlook for 2021 also is improving, thanks to the Rutledge v. PCMA decision and the prospect of state Medicaid changes in California, New York, and elsewhere.

Read on for our analysis of pharmacy profits and some thoughts on the hardy retail pharmacy survivors.

Read more »

        

Source: Post feed

The Importance of Humanity in Medication Access

Today’s guest post comes from David Holladay, President of CoverMyMeds.

David highlights the value of empathy in patient care. He also shares crucial findings from CoverMyMeds’ new 2021 Medication Access Report. This report provides a wealth of data about medication access, while also highlighting patients’ own stories and experiences.

Read on for David’s insights.

Read more »

        

Source: Post feed

Drug Channels News Roundup, January 2021: Hospital Drug Profits, Details of PBM-Manufacturer Insulin Deals, and My Favorite Chart Updated

For my first Drug Channels news roundup of 2021, I focus on two remarkable, must-read reports that provide extraordinary details about the hidden economics of our drug channel:

  • The Center for Medicare & Medicaid Services’ new transparency rule discloses how much major insurers overpay hospitals for outpatient drugs.
  • A new Senate report reveals unprecedented information about PBMs, manufacturers, and the gross-to-net bubble for insulin.

Plus, a 2021 update to my all-time favorite chart.

P.S. Join the nearly 11,000 followers of my daily links to neat stuff at @DrugChannels on Twitter. You can also join my nearly 15,000 followers on LinkedIn.

Read more »

        

Source: Post feed

Enhance Patient Care And Cost Savings By Improving Data Exchange Within The Systems You Already Have

Today’s guest post comes from Jason Coles, Senior Product Manager for Clinical Effectiveness at Wolters Kluwer, Health.

Jason discusses the benefits of accessing patient information across clinical contexts. He introduces us to the Wolters Kluwer drug data solutions. These solutions promote interoperability and help healthcare businesses meet regulations related to health information exchange.

To learn more, download the Wolters Kluwer interoperability stories ebook.

Read on for Jason’s insights.

Read more »

        

Source: Post feed

Latest CMS Data Reveal the Truth About U.S. Drug Spending

ICYMI: The econowonks at the Centers for Medicare & Medicaid Services (CMS) recently dropped the latest National Health Expenditure (NHE) data, which measures all U.S. spending on healthcare. Links below.

Today, I highlight the surprising insights from the latest figures. I examine the growth rates of major spending categories, break down costs vs. utilization, and highlight the unfavorable out-of-pocket dynamics for prescription drugs compared with hospital care.

Bonus: I also debrief you on CMS’s quinquennial comprehensive revision to the national spending data.

Regular readers know the unofficial motto of Drug Channels: “Everyone is entitled to their own opinion, but not their own facts.” For 2021, I hope the drug pricing flat earthers (#DPFE) finally start to follow the data and acknowledge what’s really going on.

Read more »

        

Source: Post feed

17th Annual Life Sciences Accounting & Reporting Congress

17th Annual Life Sciences Accounting & Reporting Congress

March 16-18, 2021 | Virtual Event

www.informaconnect.com/accounting-reporting-congress

The 17th Annual Life Sciences Accounting & Reporting Congress, an important event for finance, accounting and business leaders within life sciences, provides in-depth CPE education and networking with nearly 600 professionals. Join us for a Spring Virtual Update on March 16-18, 2021 as we navigate regulatory reform, increased complexity, dynamic risk environment, COVID industry impacts and more.

Visit www.informaconnect.com/accounting-reporting-congress for further details and to register. Drug Channels readers will save $100 off the current lowest rate when they use code DRCH100 and register prior to February 12, 2021.*

With Expert Keynotes, In-Depth Workshops and Live Q&A Opportunities and other virtual features, you’ll end your week ready to advance your organization to stay ahead in 2021.

Here’s a snapshot of what to expect:

Valuable Virtual Networking, Career Development, and Educational Opportunities:

  • Pre-Congress Offerings including Technology Solution Summits, Controller’s Think Tank, 101 Foundational Course, Talent Acquisition and Team Optimization Summit
  • CEO Fireside Chat – A Candid Conversation on Key Business and Industry Priorities in 2021 and Beyond
  • CFO Keynote Panel – Leading in Finance and Navigating the Course of Change
  • CAO Panel and Q&A – Critical Issues in Technical Accounting and Financial Reporting
  • Healthcare Policy Fireside Chat – Pricing, Policy and Healthcare Outcomes
  • SEC Keynote Address – Oversight, Management and Performance
  • FASB Address – Standards Update and Initiatives
  • Advancement Course – Future Finance: Strategies to Empower the Team, Elevate Talent, Inspire Inclusion and Cultivate a Winning Culture
  • Plus – Hot Topic Workshops focusing on AI and Robotics Automation, IPO Readiness, Clinical Trials and Vendor Study Management, Divestiture Strategies, M&A Integration, New Product Commercialization, ESG Metrics and Disclosures, Cyber and Data Security, Corporate Tax Reform Implications

Visit www.informaconnect.com/accounting-reporting-congress for further details and to register. Drug Channels readers will save $100 off the current lowest rate when they use code DRCH100 and register prior to February 12, 2021.*

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rate or non-profit rates. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

        

Source: Post feed

U.S. Prescription Trends: 2020 Review and 2021 Outlook (video)

Below is a brief excerpt from my recent Drug Channels Outlook 2021 video webinar. I discuss:

  • How COVID-19 affected the retail and mail prescription market during 2020
  • What’s ahead for prescription market

This five minute video provides you with a quick and engaging review of a year that many of us would like to forget. You can purchase a replay of the full 75-minute event, which covered many other topics.

You can also sign up for my new Drug Channels 2021 Quarterly Video Webinar Series, which includes four video webinars during 2021 (including my Outlook 2022 webinar on December 17, 2021). Let's hope this year kicks off the roaring '20s!

Read more »

        

Source: Post feed